Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Phase 1

Active, not recruiting

Conditions: Myelodysplastic Syndrome (MDS)
Myeloproliferative Neoplasms (MPNs)
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukemia (CMML)

Interventions: Drug: LY3410738
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2020-10-26

Last Posted Date: 2024-10-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 260

Registration Number: NCT04603001

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Chicago Hospital, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 34 locations

A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Dulaglutide
Drug: Insulin Glargine

First Posted Date: 2020-10-19

Last Posted Date: 2023-05-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 291

Registration Number: NCT04591626

Locations: 🇨🇳
The Second Affiliated Hospital of Zhengzhou University, Zhengzhou Shi, Henan, China
🇨🇳
The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi, Henan, China
🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

and more 24 locations

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3509754
Drug: Itraconazole
Drug: Midazolam

First Posted Date: 2020-10-14

Last Posted Date: 2022-12-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 104

Registration Number: NCT04586920

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

Phase 2

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: LY900014
Drug: Insulin Degludec

First Posted Date: 2020-10-14

Last Posted Date: 2022-06-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 31

Registration Number: NCT04585776

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Iowa Diabetes and Endocrinology Research Center, West Des Moines, Iowa, United States
🇺🇸
HealthPartners Institute dba International Diabetes Center, Minneapolis, Minnesota, United States

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Healthy
Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: LY3537021

First Posted Date: 2020-10-14

Last Posted Date: 2021-12-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 85

Registration Number: NCT04586907

Locations: 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore

A Study of LY3522348 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3522348
Drug: Placebo
Drug: Midazolam

First Posted Date: 2020-09-23

Last Posted Date: 2021-09-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 65

Registration Number: NCT04559568

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Solid Tumor

Interventions: Drug: Ramucirumab

First Posted Date: 2020-09-21

Last Posted Date: 2023-02-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 3

Registration Number: NCT04557384

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Oncology Hematology West, Omaha, Nebraska, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

and more 2 locations

A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Mirikizumab

First Posted Date: 2020-09-14

Last Posted Date: 2024-01-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT04548219

Locations: 🇺🇸
QPS, Springfield, Missouri, United States

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

Phase 1

Terminated

Conditions: Hemophilia A

Interventions: Combination Product: SIG-001

First Posted Date: 2020-09-09

Last Posted Date: 2024-01-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 3

Registration Number: NCT04541628

Locations: 🇬🇧
Clinical Study Site, Southampton, United Kingdom

A Study of LY3819253 (LY-CoV555) in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3819253
Drug: Placebo

First Posted Date: 2020-09-03

Last Posted Date: 2021-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 25

Registration Number: NCT04537910

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy